Apexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meeting

November 11, 2022

https://www.globenewswire.com/news-release/2022/11/11/2554185/0/en/Apexigen-Announces-New-Data-from-a-Phase-1-2-Trial-Evaluating-its-CD40-Antibody-Sotigalimab-in-Combination-with-Pembrolizumab-in-Patients-with-First-Line-Metastatic-Melanoma-at-the.html

– The combination of intratumoral sotigalimab and systemic pembrolizumab was well-tolerated and demonstrated an improved clinical response rate relative to the standard of care, pembrolizumab monotherapy-

Read more at globenewswire.com

Related news for (APGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.